Cai Lay Veterinary Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Cai Lay Veterinary Pharmaceutical has been growing earnings at an average annual rate of 22.6%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been declining at an average rate of 6.8% per year. Cai Lay Veterinary Pharmaceutical's return on equity is 8.4%, and it has net margins of 6.3%.
Key information
22.6%
Earnings growth rate
15.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | -6.8% |
| Return on equity | 8.4% |
| Net Margin | 6.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cai Lay Veterinary Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 109,523 | 6,891 | 21,128 | 0 |
| 31 Dec 23 | 110,906 | 6,201 | 21,539 | 0 |
| 31 Dec 22 | 119,634 | 5,904 | 21,086 | 0 |
| 31 Dec 19 | 102,410 | 1,767 | 14,185 | 0 |
| 31 Dec 18 | 134,579 | -218 | 21,187 | 0 |
Quality Earnings: MKV has high quality earnings.
Growing Profit Margin: MKV's current net profit margins (6.3%) are higher than last year (5.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MKV's earnings have grown significantly by 22.6% per year over the past 5 years.
Accelerating Growth: MKV's earnings growth over the past year (15.3%) is below its 5-year average (22.6% per year).
Earnings vs Industry: MKV earnings growth over the past year (15.3%) exceeded the Pharmaceuticals industry -10.5%.
Return on Equity
High ROE: MKV's Return on Equity (8.4%) is considered low.